tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2023-101-1-74-82tiblj-1712Research ArticleОБЗОРREVIEWСовременные представления о роли кишечной микробиоты в развитии туберкулеза легкихModern Concepts about the Role of Gut Microbiota in Development of Pulmonary TuberculosisЮнусбаеваМ. М.YunusbaevaM. M.

Юнусбаева Миляуша Мусиевна, кандидат биологических наук, старший научный сотрудник лаборатории эволюционной биомедицины

191002, Санкт-Петербург, ул. Ломоносова, д. 9

Milyausha M. Yunusbaeva, Candidate of Biological Sciences, Senior Researcher of Evolutionary Biomedicine Laboratory

9, Lomonosov St., St. Petersburg, 191002

milyaysha_ufa@mail.ruБородинаЛ. Я.BorodinaL. Ya.

Бородина Лилия Явдатовна, врач-фтизиатр высшей категории, заведующая кабинетом мониторинга туберкулеза

450080, г. Уфа, ул. С. Агиша, д. 4

Liliya Ya. Borodina, Phthisiologist, Head of Tuberculosis Monitoring Unit

4, Agisha St., Ufa, 450080

liliboro@mail.ruЗакироваА. М.ZakirovaA. M.

Закирова Айгуль Масхатовна, врач-фтизиатр, методист кабинета мониторинга туберкулеза

450080, г. Уфа, ул. С. Агиша, д. 4

Aygul M. Zakirova, Phthisiologist, Specialist of Tuberculosis Monitoring Unit

4, Agisha St., Ufa, 450080

aigul11111981@gmail.comШариповР. А.SharipovR. A.

Шарипов Рауль Ахнафович, кандидат медицинских наук, главный врач

450080, г. Уфа, ул. С. Агиша, д. 4

Raul A. Sharipov, Candidate of Medical Sciences, Head Physician

4, Agisha St., Ufa, 450080

raul-crkb@yandex.ruЮнусбаевБ. Б.YunusbayevB. B.

Юнусбаев Баязит Булатович, кандидат биологических наук, заведующий лабораторией эволюционной медицины

191002, Санкт-Петербург, ул. Ломоносова, д. 9

Bayazit B. Yunusbaev, Candidate of Biological Sciences, Head of Evolutionary Biomedicine Laboratory

9, Lomonosov St., St. Petersburg, 191002

yunusbb@inbox.ruФГАОУ ВО «Национальный исследовательский университет ИТМО»РоссияITMO UniversityRussian FederationГБУЗ «Республиканский клинический противотуберкулезный диспансер»РоссияRepublican Clinical TB DispensaryRussian FederationГБУЗ «Республиканский клинический противотуберкулезный диспансер»; ГБОУ ВО «Башкирский государственный медицинский университет»РоссияRepublican Clinical TB Dispensary; Bashkir State Medical UniversityRussian FederationФГАОУ ВО «Национальный исследовательский университет ИТМО»; Институт геномики, Тартуский университетРоссияITMO University; University of TartuRussian Federation20230603202310117482Copyright © Юнусбаева М.М., Бородина Л.Я., Закирова А.М., Шарипов Р.А., Юнусбаев Б.Б., 20232023Юнусбаева М.М., Бородина Л.Я., Закирова А.М., Шарипов Р.А., Юнусбаев Б.Б.Yunusbaeva M.M., Borodina L.Y., Zakirova A.M., Sharipov R.A., Yunusbayev B.B.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1712

В обзоре представлены данные из 55 литературных источников, описывающих взаимосвязь микробиома кишечника c туберкулезом. Обсуждаются механизмы, с помощью которых микробиота кишечника может влиять на различные звенья иммунной системы, представлены данные о влиянии противотуберкулезных препаратов на микробиом кишечника, а также возможные перспективы использования пробиотиков в лечении и профилактике туберкулеза.

The review presents data from 55 publications describing the relationship between the gut microbiome and tuberculosis. It presents possible mechanisms by which the intestinal microbiota can influence various parts of the immune system.

It describes the effect of anti-tuberculosis drugs on the intestinal microbiome as well as possible prospects for the use of probiotics in the treatment and prevention of tuberculosis.

туберкулезкишечная микробиотамикробиоммножественная лекарственная устойчивостьtuberculosisgut microbiotamicrobiomemultiple drug resistanceИсследование выполнено при финансовой поддержке Российского научного фонда (№ 22-25-00272, https://www.rscf.ru/project/22-25-00272/).This work was supported by the Russian Science Foundation (grant No. 22-25-00272, https://www.rscf.ru/project/22-25-00272/).ReferencesБелова И. В., Соловьева И. В., Точилина А. Г., Барболина С. Ф., Павлунин А. В., Шпрыков А. С. Эффективность использования нового иммобилизованного пробиотика в комплексе лечения больных туберкулезом легких // Туб. и болезни лёгких. – 2017. – Т. 95, № 5. – С. 34-40.Belova I.V., Solovyeva I.V., Tochilina A.G., Barbolina S.F., Pavlunin A.V., Shprykov A.S. Efficiency of new immobilized probiotic as a part of treatment of pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 5, pp. 34-40. (In Russ.)Пузанов В. А., Комиссарова О. Г., Никоненко Б. В. Бактериальная микробиота нижних отделов кишечника и бронхов у больных туберкулезом // Туб. и болезни лёгких. – 2020. ‒ Т. 98, № 5. – С. 37-43.Puzanov V.A., Komissarova O.G., Nikonenko B.V. Bacterial microbiota of lower gut and bronchi in tuberculosis patients. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 5, pp. 37-43. (In Russ.)Соловьева И. В., Соколова К. Я., Белова И. В., Репина Н. Б., Иванова Т. П., Точилина А. Г. Туберкулезная инфекция у детей: дополнение алгоритма лечения новым пробиотиком // Медицинский альманах. – 2009. – Т. 2, № 7. – С. 56-58.Solovyeva I.V., Sokolova K.Ya., Belova I.V., Repina N.B., Ivanova T.P., Tochilina A.G. Tuberculous infection in children: supplement to algorithm of treatment with a new probiotic. Meditsinskiy Almanakh, 2009, vol. 2, no. 7, pp. 56-58. (In Russ.)Abraham C., Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease // Gastroenterology. – 2011. Vol. 140, № 6. – Р. 1729-1737.Abraham C., Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease // Gastroenterology. – 2011. Vol. 140, № 6. – Р. 1729-1737.Aoyama M., Kotani J., Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways // Nutrition. – 2010. ‒ Vol. 26, № 6. P. 653-661.Aoyama M., Kotani J., Usami M. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways // Nutrition. – 2010. ‒ Vol. 26, № 6. P. 653-661.Arias L., Goig G. A., Cardona P. et al. Influence of gut microbiota on progression to tuberculosis generated by high fat diet-induced obesity in C3HeB/FeJ Mice // Front. Immunol. – 2019. ‒ Vol. 10. – P. 2464.Arias L., Goig G. A., Cardona P. et al. Influence of gut microbiota on progression to tuberculosis generated by high fat diet-induced obesity in C3HeB/FeJ Mice // Front. Immunol. – 2019. ‒ Vol. 10. – P. 2464.Arnold I. C., Hutchings C., Kondova I. et al. Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis // Vaccine. – 2015. ‒ Vol. 33. – P. 1808-1814.Arnold I. C., Hutchings C., Kondova I. et al. Helicobacter hepaticus infection in BALB/c mice abolishes subunit-vaccine-induced protection against M. tuberculosis // Vaccine. – 2015. ‒ Vol. 33. – P. 1808-1814.Arrieta M.-C., Stiemsma L. T., Dimitriu P. A., Thorson L., Russell S., Yurist-Doutsch S., Kuzeljevic B., Gold M. J., Britton H. M., Lefebvre D. L., Subbarao P., Mandhane P., Becker A., McNagny K. M., Sears M. R., Kollmann T., Mohn W. W., Turvey S. E., Finlay B. B. Early infancy microbial and metabolic alterations affect risk of childhood asthma // Sci. Transl. Med. – 2015. – Vol. 7, № 307. – P. 152-159.Arrieta M.-C., Stiemsma L. T., Dimitriu P. A., Thorson L., Russell S., Yurist-Doutsch S., Kuzeljevic B., Gold M. J., Britton H. M., Lefebvre D. L., Subbarao P., Mandhane P., Becker A., McNagny K. M., Sears M. R., Kollmann T., Mohn W. W., Turvey S. E., Finlay B. B. Early infancy microbial and metabolic alterations affect risk of childhood asthma // Sci. Transl. Med. – 2015. – Vol. 7, № 307. – P. 152-159.Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y. et al. Induction of colonic regulatory T cells by indigenous Clostridium species // Science. – 2011. ‒ Vol. 331. – P. 337-341.Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y. et al. Induction of colonic regulatory T cells by indigenous Clostridium species // Science. – 2011. ‒ Vol. 331. – P. 337-341.Baker M. A., Lin H.-H., Chang H.-Y., Murray M. B. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study // Clin. Infect. Dis. – 2012. – Vol. 54, № 6. – P. 818-825.Baker M. A., Lin H.-H., Chang H.-Y., Murray M. B. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study // Clin. Infect. Dis. – 2012. – Vol. 54, № 6. – P. 818-825.Bravo M., Combes T., Martinez F. O., Cerrato R., Rey J., Garcia-Jimenez W. et al. Lactobacilli isolated from wild boar (Sus scrofa) antagonize Mycobacterium bovis Bacille Calmette-Guerin (BCG) in a species-dependent manner // Front Microbiol. – 2019. ‒ Vol. 10. – P. 1663.Bravo M., Combes T., Martinez F. O., Cerrato R., Rey J., Garcia-Jimenez W. et al. Lactobacilli isolated from wild boar (Sus scrofa) antagonize Mycobacterium bovis Bacille Calmette-Guerin (BCG) in a species-dependent manner // Front Microbiol. – 2019. ‒ Vol. 10. – P. 1663.Cao A. T., Yao S., Gong B., Elson C. O., Cong Y. Th17 cells upregulate polymeric Ig receptorand intestinal IgA and contribute to intestinal homeostasis // J. Immunol. – 2012. – Vol. 189. – P. 4666-4673.Cao A. T., Yao S., Gong B., Elson C. O., Cong Y. Th17 cells upregulate polymeric Ig receptorand intestinal IgA and contribute to intestinal homeostasis // J. Immunol. – 2012. – Vol. 189. – P. 4666-4673.Cardona P., Marzo-Escartín E., Tapia G. et al. Oral administration of heat-killed Mycobacterium manresensis delays progression toward active tuberculosis in C3HeB/FeJ mice // Front Microbiol. – 2016. ‒ Vol. 6. ‒ P. 1482.Cardona P., Marzo-Escartín E., Tapia G. et al. Oral administration of heat-killed Mycobacterium manresensis delays progression toward active tuberculosis in C3HeB/FeJ mice // Front Microbiol. – 2016. ‒ Vol. 6. ‒ P. 1482.Carroll J., Draper L. A., O’Connor P. M., Coffey A., Hill C., Paul Ross, Cotter P. D., O’Mahony J. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria // Intern. J. Antimicrob. Agents. – 2010. – Vol. 36, № 2. – P. 132-136.Carroll J., Draper L. A., O’Connor P. M., Coffey A., Hill C., Paul Ross, Cotter P. D., O’Mahony J. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria // Intern. J. Antimicrob. Agents. – 2010. – Vol. 36, № 2. – P. 132-136.Chang P. V., Hao L., Offermanns S., Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings of the National Academy of Sciences of the United States of America // PNAS. – 2014. – Vol. 111, № 6. – P. 2247-2252.Chang P. V., Hao L., Offermanns S., Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proceedings of the National Academy of Sciences of the United States of America // PNAS. – 2014. – Vol. 111, № 6. – P. 2247-2252.Comberiati P., Di Cicco M., Paravati F., Pelosi U., Di Gangi A., Arasi S., Barni S., Caimmi D., Mastrorilli C., Licari A., Chiera F. The role of gut and lung microbiota in susceptibility to tuberculosis // Int. J. Envir. Res. Publ. Health 2021. ‒ Vol. 18, № 22. – P. 12220.Comberiati P., Di Cicco M., Paravati F., Pelosi U., Di Gangi A., Arasi S., Barni S., Caimmi D., Mastrorilli C., Licari A., Chiera F. The role of gut and lung microbiota in susceptibility to tuberculosis // Int. J. Envir. Res. Publ. Health 2021. ‒ Vol. 18, № 22. – P. 12220.Erturk-Hasdemir D., Oh S. F., Okan N. A. et al. Symbionts exploit complex signaling to educate the immune system // Proc. Natl. Acad. Sci. USA. – 2019. Vol. 116, №. 52. ‒ P. 26157-26166.Erturk-Hasdemir D., Oh S. F., Okan N. A. et al. Symbionts exploit complex signaling to educate the immune system // Proc. Natl. Acad. Sci. USA. – 2019. Vol. 116, №. 52. ‒ P. 26157-26166.Gavrilova N. N., Ratnikova I. A., Sadanov A. K., Bayakisheva.K., Tourlibaeva Z. J., Belikova O. A. Application of probiotics in complex treatment of tuberculosis // Int. J. Engin. Res. Applic. – 2014. ‒ Vol. 4, № 11. ‒ P. 13-18.Gavrilova N. N., Ratnikova I. A., Sadanov A. K., Bayakisheva.K., Tourlibaeva Z. J., Belikova O. A. Application of probiotics in complex treatment of tuberculosis // Int. J. Engin. Res. Applic. – 2014. ‒ Vol. 4, № 11. ‒ P. 13-18.Goldstein B. P. Resistance to rifampicin: A review // J. Antibiot. – 2014. – Vol. 67, № 9. – P. 625-630.Goldstein B. P. Resistance to rifampicin: A review // J. Antibiot. – 2014. – Vol. 67, № 9. – P. 625-630.Honda K., Littman D. R. The microbiota in adaptive immune homeostasis and disease // Nature. – 2016. – Vol. 535. – P. 75-84.Honda K., Littman D. R. The microbiota in adaptive immune homeostasis and disease // Nature. – 2016. – Vol. 535. – P. 75-84.Hu Y., Yang Q., Liu B., Dong J., Sun L., Zhu Y., Su H., Yang J., Yang F., Chen X. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs // J. Infect. ‒ 2019. – Vol. 78, № 4. – P. 317-322.Hu Y., Yang Q., Liu B., Dong J., Sun L., Zhu Y., Su H., Yang J., Yang F., Chen X. Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs // J. Infect. ‒ 2019. – Vol. 78, № 4. – P. 317-322.Hu Y., Feng Y., Wu J., Liu F., Zhang Z., Hao Y. et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients // Front. Cell Infect. Microbiol. – 2019. – Vol. 9. – P. 90.Hu Y., Feng Y., Wu J., Liu F., Zhang Z., Hao Y. et al. The gut microbiome signatures discriminate healthy from pulmonary tuberculosis patients // Front. Cell Infect. Microbiol. – 2019. – Vol. 9. – P. 90.Ivanov I. I., Atarashi K., Manel N., Brodie E. L., Shima T., Karaoz U. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria // Cell. 2009. – Vol. 139. – P. 485-498.Ivanov I. I., Atarashi K., Manel N., Brodie E. L., Shima T., Karaoz U. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria // Cell. 2009. – Vol. 139. – P. 485-498.Jeon C. Y., Murray M. B., Baker M. A. Managing tuberculosis in patients with diabetes mellitus: why we care and what we know // Exp. Rev. Anti-Inf. Ther. 2012. ‒ Vol. 10, № 8. – P. 863-868.Jeon C. Y., Murray M. B., Baker M. A. Managing tuberculosis in patients with diabetes mellitus: why we care and what we know // Exp. Rev. Anti-Inf. Ther. 2012. ‒ Vol. 10, № 8. – P. 863-868.Kaufmann S. H. Indole propionic acid: a small molecule links between gut microbiota and tuberculosis // Antimicrob. Agents Chemother. – 2018. Vol. 62. – P. e00389-18.Kaufmann S. H. Indole propionic acid: a small molecule links between gut microbiota and tuberculosis // Antimicrob. Agents Chemother. – 2018. Vol. 62. – P. e00389-18.Khaliq A., Ravindran R., Afzal S., Jena P. K., Akhtar M. W., Ambreen A. et al. Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting // PLoS ONE. 2021. – Vol. 16, № 1. P. e0245534.Khaliq A., Ravindran R., Afzal S., Jena P. K., Akhtar M. W., Ambreen A. et al. Gut microbiome dysbiosis and correlation with blood biomarkers in active-tuberculosis in endemic setting // PLoS ONE. 2021. – Vol. 16, № 1. P. e0245534.Khan N., Vidyarthi A., Nadeem S., Negi S., Nair G., Agrewala J. N. Alteration in the gut microbiota provokes susceptibility to tuberculosis // Front Immunol. 2016. – Vol. 7. – P. 529.Khan N., Vidyarthi A., Nadeem S., Negi S., Nair G., Agrewala J. N. Alteration in the gut microbiota provokes susceptibility to tuberculosis // Front Immunol. 2016. – Vol. 7. – P. 529.Khusro A., Aarti C., Mahizhaveni B., Dusthackeer A., Agastian P., Esmail G. A., Ghilan A. M., Al-Dhabi N. A., Arasu M. V. Purification and characterization of anti-tubercular and anticancer protein from Staphylococcus hominis strain MANF2: In silico structural and functional insight of peptide // Saudi J. Biol. Sci. – 2020. – Vol. 27, № 4. – P. 1107-1116.Khusro A., Aarti C., Mahizhaveni B., Dusthackeer A., Agastian P., Esmail G. A., Ghilan A. M., Al-Dhabi N. A., Arasu M. V. Purification and characterization of anti-tubercular and anticancer protein from Staphylococcus hominis strain MANF2: In silico structural and functional insight of peptide // Saudi J. Biol. Sci. – 2020. – Vol. 27, № 4. – P. 1107-1116.Kurita-Ochiai T., Ochiai K., Fukushima K. Butyric acid-induced T-cell apoptosis is mediated by caspase-8 and -9 activation in a Fas-independent manner // Clin. Diagn. Lab. Immunol. – 2001. ‒ Vol. 8, № 2. – P. 325-332.Kurita-Ochiai T., Ochiai K., Fukushima K. Butyric acid-induced T-cell apoptosis is mediated by caspase-8 and -9 activation in a Fas-independent manner // Clin. Diagn. Lab. Immunol. – 2001. ‒ Vol. 8, № 2. – P. 325-332.Lachmandas E., van den Heuvel C. N., Damen M. S., Cleophas M. C., Netea M. G., van Crevel R. Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids // J. Diab. Res. – 2016. 2016:6014631.Lachmandas E., van den Heuvel C. N., Damen M. S., Cleophas M. C., Netea M. G., van Crevel R. Diabetes Mellitus and Increased Tuberculosis Susceptibility: The Role of Short-Chain Fatty Acids // J. Diab. Res. – 2016. 2016:6014631.Lankarani K. B., Honarvar B., Athari S. S. The Mechanisms underlying helicobacter pylori-mediated protection against allergic asthma // Tanaffos. 2017. ‒ Vol. 16, № 4. – P. 251-259.Lankarani K. B., Honarvar B., Athari S. S. The Mechanisms underlying helicobacter pylori-mediated protection against allergic asthma // Tanaffos. 2017. ‒ Vol. 16, № 4. – P. 251-259.Li Y., Zhao L., Hou M., Gao T., Sun J., Luo H., Wang F., Zhong F., Ma A., Cai J. Lactobacillus casei improve anti-tuberculosis drugs-induced intestinal adverse reactions in rat by modulating gut microbiota and short-chain fatty acids // Nutrients. – 2022. – Vol. 14. – P. 1668.Li Y., Zhao L., Hou M., Gao T., Sun J., Luo H., Wang F., Zhong F., Ma A., Cai J. Lactobacillus casei improve anti-tuberculosis drugs-induced intestinal adverse reactions in rat by modulating gut microbiota and short-chain fatty acids // Nutrients. – 2022. – Vol. 14. – P. 1668.Li W., Zhu Y., Liao Q. et al. Characterization of gut microbiota in children with pulmonary tuberculosis // BMC Pediatr. ‒ 2019. – Vol. 19. – P. 445.Li W., Zhu Y., Liao Q. et al. Characterization of gut microbiota in children with pulmonary tuberculosis // BMC Pediatr. ‒ 2019. – Vol. 19. – P. 445.Liu Y., Wang J., Wu C. Microbiota and tuberculosis: a potential role of probiotics, and postbiotics // Front Nutr. – 2021. – Vol. 7, № 8. – P. 626254.Liu Y., Wang J., Wu C. Microbiota and tuberculosis: a potential role of probiotics, and postbiotics // Front Nutr. – 2021. – Vol. 7, № 8. – P. 626254.Lokesh D., Parkesh R., Kammara R. Bifidobacterium adolescentis is intrinsically resistant to antitubercular drugs // Sci. Rep. – 2018. – Vol. 8, № 1. – P. 11897.Lokesh D., Parkesh R., Kammara R. Bifidobacterium adolescentis is intrinsically resistant to antitubercular drugs // Sci. Rep. – 2018. – Vol. 8, № 1. – P. 11897.Luo M., Liu Y., Wu P., Luo D.-X., Sun Q., Zheng H., Hu R., Pandol S. J., Li Q.-F., Han Y.-P. Alternation of gut microbiota in patients with pulmonary tuberculosis // Front Physiol. – 2017. – Vol. 8. – P. 822.Luo M., Liu Y., Wu P., Luo D.-X., Sun Q., Zheng H., Hu R., Pandol S. J., Li Q.-F., Han Y.-P. Alternation of gut microbiota in patients with pulmonary tuberculosis // Front Physiol. – 2017. – Vol. 8. – P. 822.Majlessi L., Sayes F., Bureau J. et al. Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis // Mucosal. Immunol. – 2017. ‒ Vol. 10. – P. 1178-1189.Majlessi L., Sayes F., Bureau J. et al. Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis // Mucosal. Immunol. – 2017. ‒ Vol. 10. – P. 1178-1189.Namasivayam S., Maiga M., Yuan W., Thovarai V., Costa D. L., Mittereder L. R., Wipperman M. F., Glickman M. S., Dzutsev A., Trinchieri G., Sher A. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy // Microbiome. – 2017. – Vol. 5, № 1. ‒ P. 1-17.Namasivayam S., Maiga M., Yuan W., Thovarai V., Costa D. L., Mittereder L. R., Wipperman M. F., Glickman M. S., Dzutsev A., Trinchieri G., Sher A. Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy // Microbiome. – 2017. – Vol. 5, № 1. ‒ P. 1-17.Negatu D. A., Joe Liu, Zimmerman M., Kaya F., Dartois V., Aldrich C. C., Gengenbacher M., Dick T. Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular // Antimicr. Agent. Chemother. – 2018. – Vol. 62, № 3. ‒ P. 1571-1579.Negatu D. A., Joe Liu, Zimmerman M., Kaya F., Dartois V., Aldrich C. C., Gengenbacher M., Dick T. Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular // Antimicr. Agent. Chemother. – 2018. – Vol. 62, № 3. ‒ P. 1571-1579.Negatu D. A., Yamada Y., Xi Y., Go M. L., Zimmerman M., Ganapathy U., Dartois V., Gengenbacher M., Dick T. Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in Mycobacterium tuberculosis // Antimicr. Agent. Chemother. – 2019. – Vol. 10, № 2. – P. 1565-1572.Negatu D. A., Yamada Y., Xi Y., Go M. L., Zimmerman M., Ganapathy U., Dartois V., Gengenbacher M., Dick T. Gut microbiota metabolite indole propionic acid targets tryptophan biosynthesis in Mycobacterium tuberculosis // Antimicr. Agent. Chemother. – 2019. – Vol. 10, № 2. – P. 1565-1572.Rahim M. A., Seo H., Kim S. et al. In vitro anti-tuberculosis effect of probiotic Lacticaseibacillus rhamnosus PMC203 isolated from vaginal microbiota // Sci. Rep. – 2022. – Vol. 12. – P. 8290.Rahim M. A., Seo H., Kim S. et al. In vitro anti-tuberculosis effect of probiotic Lacticaseibacillus rhamnosus PMC203 isolated from vaginal microbiota // Sci. Rep. – 2022. – Vol. 12. – P. 8290.Perry S., De Jong B. C., Solnick J. V. et al. Infection with Helicobacter pylori is associated with protection against tuberculosis // PLoS One – 2010. – Vol. 5. P. e8804.Perry S., De Jong B. C., Solnick J. V. et al. Infection with Helicobacter pylori is associated with protection against tuberculosis // PLoS One – 2010. – Vol. 5. P. e8804.Round J., Mazmanian S. The gut microbiota shapes intestinal immune responses during health and disease // Nat Rev Immunol. – 2009. - № 9. - Р. 313-323.Round J., Mazmanian S. The gut microbiota shapes intestinal immune responses during health and disease // Nat Rev Immunol. – 2009. - № 9. - Р. 313-323.Schulthess J., Pandey S., Capitani M., Rue-Albrecht K. C., Arnold I., Franchini F., Chomka A., Ilott N. E., Johnston D., Pires E. et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages // Immunity. 2019. Vol. 50. – P. 432-445.Schulthess J., Pandey S., Capitani M., Rue-Albrecht K. C., Arnold I., Franchini F., Chomka A., Ilott N. E., Johnston D., Pires E. et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages // Immunity. 2019. Vol. 50. – P. 432-445.Scriba T. J., Carpenter C., Pro S. C., Sidney J., Musvosvi M., Rozot V., Seumois G., Rosales S. L., Vijayanand P., Goletti D. et al. Differential recognition of Mycobacterium tuberculosis ‒ specific epitopes as a function of tuberculosis disease history // Am. J. Respir. Crit. Care Med. – 2017. – Vol. 15. – P. 772-781.Scriba T. J., Carpenter C., Pro S. C., Sidney J., Musvosvi M., Rozot V., Seumois G., Rosales S. L., Vijayanand P., Goletti D. et al. Differential recognition of Mycobacterium tuberculosis ‒ specific epitopes as a function of tuberculosis disease history // Am. J. Respir. Crit. Care Med. – 2017. – Vol. 15. – P. 772-781.Smith P. M., Howitt M. R., Panikov N., Michaud M., Gallini C. A., Bohlooly-Y. M., Glickman J. N., Garrett W. S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis // Science. – 2013. – Vol. 341, № 6145. P. 569-573.Smith P. M., Howitt M. R., Panikov N., Michaud M., Gallini C. A., Bohlooly-Y. M., Glickman J. N., Garrett W. S. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis // Science. – 2013. – Vol. 341, № 6145. P. 569-573.van den Elsen L. W., Poyntz H. C., Weyrich L. S., Young W., Forbes-Blom E. E. Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases // Clin. Transl. Immunol. – 2017. ‒ Vol. 6, № 1. – P. e125.van den Elsen L. W., Poyntz H. C., Weyrich L. S., Young W., Forbes-Blom E. E. Embracing the gut microbiota: the new frontier for inflammatory and infectious diseases // Clin. Transl. Immunol. – 2017. ‒ Vol. 6, № 1. – P. e125.Van Rie A., Warren R., Richardson M., Victor T. C., Gie R. P., Enarson D. A., Beyers N., van Helden P. D. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment // N. Engl. J. Med. – 1999. – Vol. 341. P. 1174-1179.Van Rie A., Warren R., Richardson M., Victor T. C., Gie R. P., Enarson D. A., Beyers N., van Helden P. D. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment // N. Engl. J. Med. – 1999. – Vol. 341. P. 1174-1179.Verver S., Warren R. M., Beyers N., Richardson M., van der Spuy G. D., Borgdorff M. W., Enarson D. A., Behr M. A., van Helden P. D. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis // Am. J. Respir. Crit. Care Med. – 2005. Vol. 171. – P. 1430-1435.Verver S., Warren R. M., Beyers N., Richardson M., van der Spuy G. D., Borgdorff M. W., Enarson D. A., Behr M. A., van Helden P. D. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis // Am. J. Respir. Crit. Care Med. – 2005. Vol. 171. – P. 1430-1435.Wang J., Xiong K., Zhao S., Zhang C., Zhang J., Xu L. et al. Long-term effects of multi-drug-resistant tuberculosis treatment on gut microbiota and its health consequences // Front Microbiol. – 2020. – Vol. 11. – P. 53.Wang J., Xiong K., Zhao S., Zhang C., Zhang J., Xu L. et al. Long-term effects of multi-drug-resistant tuberculosis treatment on gut microbiota and its health consequences // Front Microbiol. – 2020. – Vol. 11. – P. 53.Winglee K., Eloe-Fadrosh E., Gupta S., Guo H., Fraser C., Bishai W. Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota // PLoS One. – 2014. – Vol. 9, № 5. ‒ P. 97048.Winglee K., Eloe-Fadrosh E., Gupta S., Guo H., Fraser C., Bishai W. Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota // PLoS One. – 2014. – Vol. 9, № 5. ‒ P. 97048.Wipperman M. F., Fitzgerald D. W., Juste M. A. J., Taur Y., Namasivayam S., Sher A., Bean J. M., Bucci V., Glickman M. S. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed // Sci. Rep. – 2017. – Vol. 7, № 1. – P. 10767.Wipperman M. F., Fitzgerald D. W., Juste M. A. J., Taur Y., Namasivayam S., Sher A., Bean J. M., Bucci V., Glickman M. S. Antibiotic treatment for tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed // Sci. Rep. – 2017. – Vol. 7, № 1. – P. 10767.Wood M. R., Yu E. A., Mehta S. The human microbiome in the fight against tuberculosis // Am. J. Trop. Med. Hyg. – 2017. Vol. 96, № 6. – P. 1274-1284.Wood M. R., Yu E. A., Mehta S. The human microbiome in the fight against tuberculosis // Am. J. Trop. Med. Hyg. – 2017. Vol. 96, № 6. – P. 1274-1284.Zheng D., Liwinski T., Elinav E. Interaction between microbiota and immunity in health and disease // Cell. Res. – 2020. – Vol. 30. – P. 492-506.Zheng D., Liwinski T., Elinav E. Interaction between microbiota and immunity in health and disease // Cell. Res. – 2020. – Vol. 30. – P. 492-506.Zuo Z. T., Ma Y., Sun Y., Bai C. Q.., Ling C H., Yuan F. L. The protective effects of Helicobacter pylori infection on allergic asthma // Int. Arch. Allergy Immunol. 2021. – Vol. 182, № 1. – P. 53-64.Zuo Z. T., Ma Y., Sun Y., Bai C. Q.., Ling C H., Yuan F. L. The protective effects of Helicobacter pylori infection on allergic asthma // Int. Arch. Allergy Immunol. 2021. – Vol. 182, № 1. – P. 53-64.

The authors declare that there are no conflicts of interest present.